Lena Söderström appointed Biotech Builder 2018
"Being awarded for this year's Biotech Builder is honorable and an award that of course affects all of us who for several years worked strategically to take Senzime from a development company to a commercial company with presence on approximately 15 markets. We continually strenghten our market position by signing additional distributor agreements on new markets”, says Lena Söderström, CEO Senzime AB.
Biotech Builders is an informal and independent network organization that started in Denmark 2002 and in Sweden 2009. The organization itself acknowledges that the annual Biotech Builder Award goes to people who have contributed to significant advances within Life Science and whom inspire to further development.
For further information, please contact:
Lena Söderström, CEO of Senzime AB
+46 708-16 39 12, email@example.com
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com